Global Drugs for Anti-Infective Market Insights and Forecast to 2026

1 Study Coverage

• 1.1 Drugs for Anti-Infective Product Introduction
• 1.2 Market Segments
• 1.3 Key Drugs for Anti-Infective Manufacturers Covered: Ranking by Revenue
• 1.4 Market by Type
  • 1.4.1 Global Drugs for Anti-Infective Market Size Growth Rate by Type
  • 1.4.2 OTC
  • 1.4.3 Rx Drugs
• 1.5 Market by Application
  • 1.5.1 Global Drugs for Anti-Infective Market Size Growth Rate by Application
  • 1.5.2 Hospital
  • 1.5.3 Drugs Store
  • 1.5.4 Other
• 1.6 Study Objectives
• 1.7 Years Considered

2 Executive Summary

• 2.1 Global Drugs for Anti-Infective Market Size, Estimates and Forecasts
  • 2.1.1 Global Drugs for Anti-Infective Revenue 2015-2026
  • 2.1.2 Global Drugs for Anti-Infective Sales 2015-2026
• 2.2 Global Drugs for Anti-Infective, Market Size by Producing Regions: 2015 VS 2020 VS 2026
  • 2.2.1 Global Drugs for Anti-Infective Retrospective Market Scenario in Sales by Region: 2015-2020
  • 2.2.2 Global Drugs for Anti-Infective Retrospective Market Scenario in Revenue by Region: 2015-2020

3 Global Drugs for Anti-Infective Competitor Landscape by Players

• 3.1 Drugs for Anti-Infective Sales by Manufacturers
  • 3.1.1 Drugs for Anti-Infective Sales by Manufacturers (2015-2020)
  • 3.1.2 Drugs for Anti-Infective Sales Market Share by Manufacturers (2015-2020)
• 3.2 Drugs for Anti-Infective Revenue by Manufacturers
  • 3.2.1 Drugs for Anti-Infective Revenue by Manufacturers (2015-2020)
  • 3.2.2 Drugs for Anti-Infective Revenue Share by Manufacturers (2015-2020)
  • 3.2.3 Global Drugs for Anti-Infective Market Concentration Ratio (CR5 and HHI) (2015-2020)
  • 3.2.4 Global Top 10 and Top 5 Companies by Drugs for Anti-Infective Revenue in 2019
  • 3.2.5 Global Drugs for Anti-Infective Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.3 Drugs for Anti-Infective Price by Manufacturers
• 3.4 Drugs for Anti-Infective Manufacturing Base Distribution, Product Types
  • 3.4.1 Drugs for Anti-Infective Manufacturers Manufacturing Base Distribution, Headquarters
  • 3.4.2 Manufacturers Drugs for Anti-Infective Product Type
  • 3.4.3 Date of International Manufacturers Enter into Drugs for Anti-Infective Market
• 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)

• 4.1 Global Drugs for Anti-Infective Market Size by Type (2015-2020)
  • 4.1.1 Global Drugs for Anti-Infective Sales by Type (2015-2020)
  • 4.1.2 Global Drugs for Anti-Infective Revenue by Type (2015-2020)
  • 4.1.3 Drugs for Anti-Infective Average Selling Price (ASP) by Type (2015-2026)
• 4.2 Global Drugs for Anti-Infective Market Size Forecast by Type (2021-2026)
  • 4.2.1 Global Drugs for Anti-Infective Sales Forecast by Type (2021-2026)
  • 4.2.2 Global Drugs for Anti-Infective Revenue Forecast by Type (2021-2026)
  • 4.2.3 Drugs for Anti-Infective Average Selling Price (ASP) Forecast by Type (2021-2026)
• 4.3 Global Drugs for Anti-Infective Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Market Size by Application (2015-2026)

• 5.1 Global Drugs for Anti-Infective Market Size by Application (2015-2020)
  • 5.1.1 Global Drugs for Anti-Infective Sales by Application (2015-2020)
  • 5.1.2 Global Drugs for Anti-Infective Revenue by Application (2015-2020)
  • 5.1.3 Drugs for Anti-Infective Price by Application (2015-2020)
• 5.2 Drugs for Anti-Infective Market Size Forecast by Application (2021-2026)
  • 5.2.1 Global Drugs for Anti-Infective Sales Forecast by Application (2021-2026)
  • 5.2.2 Global Drugs for Anti-Infective Revenue Forecast by Application (2021-2026)
  • 5.2.3 Global Drugs for Anti-Infective Price Forecast by Application (2021-2026)

6 North America

• 6.1 North America Drugs for Anti-Infective by Country
  • 6.1.1 North America Drugs for Anti-Infective Sales by Country
  • 6.1.2 North America Drugs for Anti-Infective Revenue by Country
  • 6.1.3 U.S.
  • 6.1.4 Canada
• 6.2 North America Drugs for Anti-Infective Market Facts & Figures by Type
• 6.3 North America Drugs for Anti-Infective Market Facts & Figures by Application

7 Europe

• 7.1 Europe Drugs for Anti-Infective by Country
  • 7.1.1 Europe Drugs for Anti-Infective Sales by Country
  • 7.1.2 Europe Drugs for Anti-Infective Revenue by Country
  • 7.1.3 Germany
  • 7.1.4 France
  • 7.1.5 U.K.
  • 7.1.6 Italy
  • 7.1.7 Russia
• 7.2 Europe Drugs for Anti-Infective Market Facts & Figures by Type
• 7.3 Europe Drugs for Anti-Infective Market Facts & Figures by Application

8 Asia Pacific

• 8.1 Asia Pacific Drugs for Anti-Infective by Region
  • 8.1.1 Asia Pacific Drugs for Anti-Infective Sales by Region
  • 8.1.2 Asia Pacific Drugs for Anti-Infective Revenue by Region
  • 8.1.3 China
  • 8.1.4 Japan
  • 8.1.5 South Korea
  • 8.1.6 India
  • 8.1.7 Australia
  • 8.1.8 Taiwan
  • 8.1.9 Indonesia
  • 8.1.10 Thailand
  • 8.1.11 Malaysia
  • 8.1.12 Philippines
  • 8.1.13 Vietnam
• 8.2 Asia Pacific Drugs for Anti-Infective Market Facts & Figures by Type
• 8.3 Asia Pacific Drugs for Anti-Infective Market Facts & Figures by Application

9 Latin America

• 9.1 Latin America Drugs for Anti-Infective by Country
  • 9.1.1 Latin America Drugs for Anti-Infective Sales by Country
  • 9.1.2 Latin America Drugs for Anti-Infective Revenue by Country
  • 9.1.3 Mexico
  • 9.1.4 Brazil
  • 9.1.5 Argentina
• 9.2 Central & South America Drugs for Anti-Infective Market Facts & Figures by Type
• 9.3 Central & South America Drugs for Anti-Infective Market Facts & Figures by Application

10 Middle East and Africa

• 10.1 Middle East and Africa Drugs for Anti-Infective by Country
  • 10.1.1 Middle East and Africa Drugs for Anti-Infective Sales by Country
  • 10.1.2 Middle East and Africa Drugs for Anti-Infective Revenue by Country
  • 10.1.3 Turkey
  • 10.1.4 Saudi Arabia
  • 10.1.5 U.A.E
• 10.2 Middle East and Africa Drugs for Anti-Infective Market Facts & Figures by Type
• 10.3 Middle East and Africa Drugs for Anti-Infective Market Facts & Figures by Application

11 Company Profiles

• 11.1 GlaxoSmithKline
  • 11.1.1 GlaxoSmithKline Corporation Information
  • 11.1.2 GlaxoSmithKline Description and Business Overview
  • 11.1.3 GlaxoSmithKline Sales, Revenue and Gross Margin (2015-2020)
  • 11.1.4 GlaxoSmithKline Drugs for Anti-Infective Products Offered
  • 11.1.5 GlaxoSmithKline Related Developments
• 11.2 Merck
  • 11.2.1 Merck Corporation Information
  • 11.2.2 Merck Description and Business Overview
  • 11.2.3 Merck Sales, Revenue and Gross Margin (2015-2020)
  • 11.2.4 Merck Drugs for Anti-Infective Products Offered
  • 11.2.5 Merck Related Developments
• 11.3 Pfizer
  • 11.3.1 Pfizer Corporation Information
  • 11.3.2 Pfizer Description and Business Overview
  • 11.3.3 Pfizer Sales, Revenue and Gross Margin (2015-2020)
  • 11.3.4 Pfizer Drugs for Anti-Infective Products Offered
  • 11.3.5 Pfizer Related Developments
• 11.4 Novartis AG
  • 11.4.1 Novartis AG Corporation Information
  • 11.4.2 Novartis AG Description and Business Overview
  • 11.4.3 Novartis AG Sales, Revenue and Gross Margin (2015-2020)
  • 11.4.4 Novartis AG Drugs for Anti-Infective Products Offered
  • 11.4.5 Novartis AG Related Developments
• 11.5 Gilead Sciences
  • 11.5.1 Gilead Sciences Corporation Information
  • 11.5.2 Gilead Sciences Description and Business Overview
  • 11.5.3 Gilead Sciences Sales, Revenue and Gross Margin (2015-2020)
  • 11.5.4 Gilead Sciences Drugs for Anti-Infective Products Offered
  • 11.5.5 Gilead Sciences Related Developments
• 11.6 Abbott
  • 11.6.1 Abbott Corporation Information
  • 11.6.2 Abbott Description and Business Overview
  • 11.6.3 Abbott Sales, Revenue and Gross Margin (2015-2020)
  • 11.6.4 Abbott Drugs for Anti-Infective Products Offered
  • 11.6.5 Abbott Related Developments
• 11.7 Wyeth
  • 11.7.1 Wyeth Corporation Information
  • 11.7.2 Wyeth Description and Business Overview
  • 11.7.3 Wyeth Sales, Revenue and Gross Margin (2015-2020)
  • 11.7.4 Wyeth Drugs for Anti-Infective Products Offered
  • 11.7.5 Wyeth Related Developments
• 11.8 Sanofi-Aventis
  • 11.8.1 Sanofi-Aventis Corporation Information
  • 11.8.2 Sanofi-Aventis Description and Business Overview
  • 11.8.3 Sanofi-Aventis Sales, Revenue and Gross Margin (2015-2020)
  • 11.8.4 Sanofi-Aventis Drugs for Anti-Infective Products Offered
  • 11.8.5 Sanofi-Aventis Related Developments
• 11.9 Bristol-Myers Squibb
  • 11.9.1 Bristol-Myers Squibb Corporation Information
  • 11.9.2 Bristol-Myers Squibb Description and Business Overview
  • 11.9.3 Bristol-Myers Squibb Sales, Revenue and Gross Margin (2015-2020)
  • 11.9.4 Bristol-Myers Squibb Drugs for Anti-Infective Products Offered
  • 11.9.5 Bristol-Myers Squibb Related Developments
• 11.10 Johnson
  • 11.10.1 Johnson Corporation Information
  • 11.10.2 Johnson Description and Business Overview
  • 11.10.3 Johnson Sales, Revenue and Gross Margin (2015-2020)
  • 11.10.4 Johnson Drugs for Anti-Infective Products Offered
  • 11.10.5 Johnson Related Developments
• 11.1 GlaxoSmithKline
  • 11.1.1 GlaxoSmithKline Corporation Information
  • 11.1.2 GlaxoSmithKline Description and Business Overview
  • 11.1.3 GlaxoSmithKline Sales, Revenue and Gross Margin (2015-2020)
  • 11.1.4 GlaxoSmithKline Drugs for Anti-Infective Products Offered
  • 11.1.5 GlaxoSmithKline Related Developments
• 11.12 Nanosphere
  • 11.12.1 Nanosphere Corporation Information
  • 11.12.2 Nanosphere Description and Business Overview
  • 11.12.3 Nanosphere Sales, Revenue and Gross Margin (2015-2020)
  • 11.12.4 Nanosphere Products Offered
  • 11.12.5 Nanosphere Related Developments
• 11.13 NanoViricides
  • 11.13.1 NanoViricides Corporation Information
  • 11.13.2 NanoViricides Description and Business Overview
  • 11.13.3 NanoViricides Sales, Revenue and Gross Margin (2015-2020)
  • 11.13.4 NanoViricides Products Offered
  • 11.13.5 NanoViricides Related Developments
• 11.14 Novabay Pharmaceuticals
  • 11.14.1 Novabay Pharmaceuticals Corporation Information
  • 11.14.2 Novabay Pharmaceuticals Description and Business Overview
  • 11.14.3 Novabay Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
  • 11.14.4 Novabay Pharmaceuticals Products Offered
  • 11.14.5 Novabay Pharmaceuticals Related Developments
• 11.15 Obetech
  • 11.15.1 Obetech Corporation Information
  • 11.15.2 Obetech Description and Business Overview
  • 11.15.3 Obetech Sales, Revenue and Gross Margin (2015-2020)
  • 11.15.4 Obetech Products Offered
  • 11.15.5 Obetech Related Developments
• 11.16 Optimer Pharmaceuticals
  • 11.16.1 Optimer Pharmaceuticals Corporation Information
  • 11.16.2 Optimer Pharmaceuticals Description and Business Overview
  • 11.16.3 Optimer Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
  • 11.16.4 Optimer Pharmaceuticals Products Offered
  • 11.16.5 Optimer Pharmaceuticals Related Developments
• 11.17 Basilea Pharmaceutica AG
  • 11.17.1 Basilea Pharmaceutica AG Corporation Information
  • 11.17.2 Basilea Pharmaceutica AG Description and Business Overview
  • 11.17.3 Basilea Pharmaceutica AG Sales, Revenue and Gross Margin (2015-2020)
  • 11.17.4 Basilea Pharmaceutica AG Products Offered
  • 11.17.5 Basilea Pharmaceutica AG Related Developments
• 11.18 Daiichi Sankyo
  • 11.18.1 Daiichi Sankyo Corporation Information
  • 11.18.2 Daiichi Sankyo Description and Business Overview
  • 11.18.3 Daiichi Sankyo Sales, Revenue and Gross Margin (2015-2020)
  • 11.18.4 Daiichi Sankyo Products Offered
  • 11.18.5 Daiichi Sankyo Related Developments
• 11.19 MerLion Pharma
  • 11.19.1 MerLion Pharma Corporation Information
  • 11.19.2 MerLion Pharma Description and Business Overview
  • 11.19.3 MerLion Pharma Sales, Revenue and Gross Margin (2015-2020)
  • 11.19.4 MerLion Pharma Products Offered
  • 11.19.5 MerLion Pharma Related Developments
• 11.20 Theravance
  • 11.20.1 Theravance Corporation Information
  • 11.20.2 Theravance Description and Business Overview
  • 11.20.3 Theravance Sales, Revenue and Gross Margin (2015-2020)
  • 11.20.4 Theravance Products Offered
  • 11.20.5 Theravance Related Developments

12 Future Forecast by Regions (Countries) (2021-2026)

• 12.1 Drugs for Anti-Infective Market Estimates and Projections by Region
  • 12.1.1 Global Drugs for Anti-Infective Sales Forecast by Regions 2021-2026
  • 12.1.2 Global Drugs for Anti-Infective Revenue Forecast by Regions 2021-2026
• 12.2 North America Drugs for Anti-Infective Market Size Forecast (2021-2026)
  • 12.2.1 North America: Drugs for Anti-Infective Sales Forecast (2021-2026)
  • 12.2.2 North America: Drugs for Anti-Infective Revenue Forecast (2021-2026)
  • 12.2.3 North America: Drugs for Anti-Infective Market Size Forecast by Country (2021-2026)
• 12.3 Europe Drugs for Anti-Infective Market Size Forecast (2021-2026)
  • 12.3.1 Europe: Drugs for Anti-Infective Sales Forecast (2021-2026)
  • 12.3.2 Europe: Drugs for Anti-Infective Revenue Forecast (2021-2026)
  • 12.3.3 Europe: Drugs for Anti-Infective Market Size Forecast by Country (2021-2026)
• 12.4 Asia Pacific Drugs for Anti-Infective Market Size Forecast (2021-2026)
  • 12.4.1 Asia Pacific: Drugs for Anti-Infective Sales Forecast (2021-2026)
  • 12.4.2 Asia Pacific: Drugs for Anti-Infective Revenue Forecast (2021-2026)
  • 12.4.3 Asia Pacific: Drugs for Anti-Infective Market Size Forecast by Region (2021-2026)
• 12.5 Latin America Drugs for Anti-Infective Market Size Forecast (2021-2026)
  • 12.5.1 Latin America: Drugs for Anti-Infective Sales Forecast (2021-2026)
  • 12.5.2 Latin America: Drugs for Anti-Infective Revenue Forecast (2021-2026)
  • 12.5.3 Latin America: Drugs for Anti-Infective Market Size Forecast by Country (2021-2026)
• 12.6 Middle East and Africa Drugs for Anti-Infective Market Size Forecast (2021-2026)
  • 12.6.1 Middle East and Africa: Drugs for Anti-Infective Sales Forecast (2021-2026)
  • 12.6.2 Middle East and Africa: Drugs for Anti-Infective Revenue Forecast (2021-2026)
  • 12.6.3 Middle East and Africa: Drugs for Anti-Infective Market Size Forecast by Country (2021-2026)

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

• 13.1 Market Opportunities and Drivers
• 13.2 Market Challenges
• 13.3 Market Risks/Restraints
• 13.4 Porter's Five Forces Analysis
• 13.5 Primary Interviews with Key Drugs for Anti-Infective Players (Opinion Leaders)

14 Value Chain and Sales Channels Analysis

• 14.1 Value Chain Analysis
• 14.2 Drugs for Anti-Infective Customers
• 14.3 Sales Channels Analysis
  • 14.3.1 Sales Channels
  • 14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix

• 16.1 Research Methodology
  • 16.1.1 Methodology/Research Approach
  • 16.1.2 Data Source
• 16.2 Author Details